Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 7, 2009, Pages 1190-1194

  Salama, Noha N ^a,c,d   Segal, Jonathan H ^b,c   Churchwell, Mariann D ^c,e   Patel, Jignesh H ^c,f   Gao, Lihong ^g   Heung, Michael ^b,c   Mueller, Bruce A ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Renal Replacement Therapy Kinetics Study Group   (United States)

^d CAIRO UNIVERSITY   (Egypt)

^e UNIVERSITY OF TOLEDO   (United States)

^f University of Kentucky   (United States)

^g Cubist Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; POLYSULFONE; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL KIDNEY; BACTERIAL INFECTION; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; AGED; BIOLOGICAL MODEL; BLOOD; CHRONIC KIDNEY FAILURE; FEASIBILITY STUDY; GRAM POSITIVE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; DAPTOMYCIN; FEASIBILITY STUDIES; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 70349329894     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01650309     Document Type: Article

References (14)

1. Pai AB, Pai MP: Optimizing antimicrobial therapy for Gram-positive bloodstream infections in patients on hemodialysis. Adv Chronic Kidney Dis 13: 259-270, 2006
2. Cubicin: Full Prescribing Information, Lexington, MA, Cubist Pharmaceuticals, Inc., 2008
3. Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA: Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 17: 256-262, 1997
4. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA: Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 46: 681-687, 2005
5. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD: Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: Post-dialysis versus intradialytic administration. Clin Nephrol 60: 96-104, 2003
6. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA: Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 50: 51-55, 1998
7. Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, Oleson FB Jr: Daptomycin: A novel agent for Gram-positive infections. Expert Opin Investig Drugs 8: 1223-1238, 1999
8. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45: 845-851, 2001
9. Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48: 63-68, 2004
10. Benvenuto M, Benziger DP, Yankelev S, Vigliani G: Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50: 3245-3249, 2006
11. Woodworth JR, Nyhart EHJ, Brier GL, Wolny JD, Black HR: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36: 318-325, 1992
12. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47: 1318-1323, 2003
13. Dvorchik BH, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H: Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48: 2799-2807, 2004
14. Sica DA, Gehr T, Dvorchik BH: Pharmacokinetics and safety of single dose daptomycin in subjects with graded renal insufficiency and end stage renal disease [Abstract 2257]. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA